Winter 2020 / 2021 - MEDICINE EVOLVED - Webflow
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
M E D I C I N E E V O L V E D
Winter 2020 / 2021
Disclaimer
General
The information provided in this presentation pertaining to Mydecine Innovations Group Inc. ("Mydecine" or the "Company"), its business assets, strategy and operations is for general informational purposes only
and is not a formal offer to sell or a solicitation of an offer to buy any securities, options, futures, or other derivatives related to securities in any jurisdiction and its content is not prescribed by securities laws.
Information contained in this presentation should not be relied upon as advice to buy or sell or hold such securities or as an offer to sell such securities. This presentation does not take into account nor does it
provide any tax, legal or investment advice or opinion regarding the specific investment objectives or financial situation of any person. While the information in this presentation is believed to be accurate and
reliable, Mydecine and its agents, advisors, directors, officers, employees and shareholders make no representation or warranties, expressed or implied, as to the accuracy of such information and Mydecine
expressly disclaims any and all liability that may be based on such information or errors or omissions thereof.
Mydecine reserves the right to amend or replace the information contained herein, in part or entirely, at any time, and undertakes no obligation to provide the recipient with access to the amended information or
to notify the recipient thereof. The information contained in this presentation is intended only for the persons to whom it is transmitted for the purposes of evaluating the Company. The information contained in
this presentation supersedes any prior presentation or conversation concerning the Company. Any information, representations or statements not contained herein shall not be relied upon for any purpose.
Neither we nor any of our representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this presentation by you or
any of your representatives or for omissions from the information in this presentation. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made by, third parties
in respect of the matters discussed in this presentation.
Confidentiality
This presentation is confidential and is intended, among other things, to present a general outline of the Company. The contents are not to be reproduced or distributed to the public or press.
Each person who has received a copy of this presentation (whether or not such person purchases any securities) is deemed to have agreed: (i) not to reproduce or distribute this presentation, in whole or in part,
without the prior written consent of the Company, other than to legal, tax, financial and other advisors on a need to know basis, (ii) if such person has not purchased securities, to return this presentation to the
Company upon its request, (iii) without the prior written consent of the Company, not to disclose any information contained in this presentation except to the extent that such information was (a) previously known by
such person through a source (other than the Company) not bound by any obligation to keep such information confidential, (b) in the public domain through no fault of such person, or (c) lawfully obtained at a later
date by such persfrom sources (other than the Company) not bound by any obligation to keep such information confidential, and (iv) to be responsible for any disclosure of this presentation, or the information
contained herein, by such person or any of its employees, agents or representatives.
Forward Looking Statements
Certain information set forth in this presentation contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred
to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial
performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures;
(iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) comple-
tion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vi) renewal of the Company’s current customer, supplier and other material agreements; and (vii) future
liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so
that they may use such beliefs and opinions as one factor in evaluating an investment.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties,
which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking state-
ments will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if
circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
v
M E D I C I N E E V O L V E D
Mydecine Innovations Group™ (CSE: MYCO) (OTC:MYCOF) (FSE:0NFA) is an emerging biotech and life sciences company dedicated to developing and commercializing
innovative solutions for treating mental health problems and enhancing vitality. The company’s world-renowned medical and scientific advisory board is building out a robust
R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems. Mydecine has exclusive access to a full
cGMP certified pharmaceutical manufacturing facility with the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds with full government
approval through Health Canada. Mydecine also operates out of a state-of-the-art mycology lab in Denver, CO to focus on genetic research for scaling commercial cultivation
of rare (non-psychedelic) medicinal mushrooms.
At the heart of Mydecine’s core philosophy is that psychedelic-assisted psychotherapy will continue to gain acceptance in the medical community with many of the world’s
best accredited research organizations demonstrating its remarkable clinical effectiveness. Mydecine recognizes the responsibility associated with psychedelic-assisted
therapy and will continue to position itself as a long-term leader across the spectrum of clinical trials, research, technology, and global supply. Mydecine has also successfully
completed multiple acquisitions since its inception.
z
1
Mydecine™ is a Leader in
M E D I C I N E E V O L V E D
Psychedelic Therapeutics
Mydecine is a vertically integrated life sciences company dedicated to developing and commercializing innovative solutions for treating
mental health problems and enhancing vitality. Through the companies three main focuses R&D and IP, Clinical Trials and Technology,
Mydecine has a thorough and well rounded approach to change the way we treat mental health.
✓IP & R&D ✓CLINICAL TRIALS ✓TECHNOLOGY
Mydecine is able to oversee all areas of Phase 2A clinical on PTSD in veterans, EMS Mindleap's proprietary digital health platform
drug development including synthesis, and front line workers with global test sites allows Mydecine to generate revenue in the
genetic research, import/export, delivery currently approved at Leiden University, fast-growing USD $41.4 billion telemedicine
system development, clinical trial execution, University Of Alberta, Royal Ottawa Hospital, market
product commercialization and distribution Western Onterio University and finalizing
several VA sites in the United States including Mindleap is a first mover in this emerging market
Seven patent pending applications that Boston, New York, LA and San Diego and is focused on expanding services and digital
represent thousands of inventions with products across.conventional mental health
multiple layers of protection on the companies Large scale Microdose study co-sponsored by treatments to generate revenue as psychedelic
proprietary drug development pipeline the National Institute for Health Research at therapies get approved
Imperial College of London with Mydecine SAB
member Dr. David Erritzoe Mindleap has over 50 Mental Health Providers,
Expert interdisciplinary team and state of the
combines telemedicine with mental health
art infrastructure allowing for accelerated drug
First-of-Its-kind Microdose study at Mcquery analytics, is HIPAA/GDPR/PIPEDA compliant,
development process
University in Australia with Mydecine SAB and is available to download on Android & IOS
Several novel molecule designs by some of the Dr. Vince Polito
worlds top drug discovery and design experts
including Dr. Denton Hoyer formerly with Sponsoring preclinical animal work from
Novartis, Pfizer and Yale as well as the faculty of University of Maryland aimed at a mechanistic
pharmacology at the University of Alberta understanding of psilocybin Medicine Evolved
Finalizing plans on late stage addiction study 1
Leading The Renaissance
of Cutting-Edge Medicine
✓ First legal nature-sourced psilocybin extraction
✓ First legal commercial export of psilocybin mushrooms
✓ Launched first psychedelics focused telehealth platform,
Mindleap Health
✓ Launched first ever psilocybin clinical trials with veterans with
PTSD indications
✓ First company to achieve cGMP status for Psychedelic mushroom
products for production, sale, and export
✓ Discovered several novel active molecules never found in natural
sourced fungal sources
✓ First-of-Its-kind Microdose study at Mcquery University in Australia
Medicine Evolved
22
“Mental disorders are on the rise in every country in the
Tackling Mental Health's world and will cost the global economy $16 trillion by 2030”
- Lancet Commission, Oct 10, 2018
Biggest Problems with Our Solutions
z
300 ? only
450 30 %
million million 11 %
People suffer from Lacking help and Mental health is lacking data- of veterans will develop PTSD of people with addiction
mental health issues 100M+ unresponsive driven solutions, especially in disorders receive any form of
to treatment specialist contexts treatment
World Wide
Our Solution: There are currently
Our Solution: Create novel Our Solution: Create passive no pharmaceutical drugs Our Solution: Psilocybin assisted
Our Solution: Create highly cost effective medicine, and monitoring systems and train developed for PTSD. psychotherapy clinical studies on
scalable treatments including compliment primary offerings predictive models to use these as Current prescribed options have various forms of addiction at universities
digital therapeutics + virtual with affordable mental health proxies for mental health states and significant side effects and are such as NYU, New Mexico and Johns
specialist sessions. digital solutions that can be share this information with users mainly ineffective. Initial clinical Hopkins have shown success rates as
accessed from anywhere. and mental health specialists. findings from psilocybin assisted high as 80%. Combined with little to no
psychotherapy are showing side effects and the relative ease of
success rates as high as 80%. treatments we anticipate the
participation rate to rise dramatically.
3
Better Health and Vitality with
Fungtional™ Medicinal Mushrooms
Consumers are shifting away from synthetic chemicals, harmful
supplements, and unhealthy food products, in recognition of increased
health benefits and a better lifestyle.
Our answer: Conducting scientific research & focusing on IP to be the
world’s leaders in providing raw bulk isolated active compounds found
in numerous functional medicinal mushrooms.
150 Post
million Pandemic
Americans
45% of the population Our world is forever changed
have one or more chronic diseases, in the with the advent of Covid 19. People are looking
midst of the most serious pandemic in 100 for new solutions to build their immune system
years. As a result, Americans are searching and stay healthier by ingesting less synthetic food
for healthier products more than ever products and consuming more organic plant
before. based snacks, meals, and drinks to help their
body minimize the growth and spread of any
Our Answer: Mydecine is taking a head-first disease in their system.
approach into discovering and developing
Our Answer: Mydecine is focused on helping
natural compounds found in fungi, and people build stronger immune systems by
infusing these into a new category of vitality producing new medicinal fungi-based ingredients.
products. Medicine Evolved
4
Global Healing Opportunity
Addiction PTSD
v
$ 1.4 trillion globally in 11 people
1globally
The Economic Costs of Smoking will be diagnosed
(Health Expenditures and Productivity with PTSD in their lifetime
Losses together)
The Global smoking cessation
up to 30 %
market is expected to reach of veterans will develop PTSD
$ 64 billion every 72 minutes
a US veteran commits suicide
107 million
people globally are addicted 4x the global average
to alcohol consumption frontline workers developing PTSD
7.1 million deaths Anxiety
per year globally due to
smoking related causes
275 million
people suffer from some
15 % of all global deaths are
attributed to smoking
form of anxiety globally
Medicine Evolved
5
Our Revolution in Health Science
We are actively leveraging relationships with scientific, medical, military, and clinical organizations
propelling Mydecine to the forefront of the market. Our current research in microdosing, drug
development, and clinical trials beginning with veterans with PTSD indications is at the cutting
edge of the category.
Mydecine Snapshot Mydecine Team
✓ World-renowned Medical & Scientific Advisory Board ✓ Accomplished entrepreneurs, multiple successful exits
✓ Proven drug development and approval experience
✓ Schedule 1 Drugs and Substances Dealer’s License through
Health Canada ✓ Over 20 experienced research scientists
✓ Robust clinical trial pipeline ✓ 30+ years of combined psychedelic industry experience
✓ Deep intellectual property portfolio ✓ 100+ published peer-reviewed studies / papers
✓ State-of-the-art mycology laboratory for genetic R&D ✓ World-class team drawn from Pfizer, Novartis, Yale, Imperial
✓ Unparalleled global relationships with veteran organizations College London, and Canadian, US and EU Militaries
✓ Launched an advanced digital telehealth platform ✓ Held top mental health positions in organizations such as
NATO, Canadian Armed Forces and the DOD
1
6
The Ecosystem of Mydecine
Cultivating rare and unique fungi species Growing + Processing
Growing + Processing Valuable Mushrooms
Valuable Mushrooms for clinical research and for fungtional™
health and vitality products
Extracting + Isolating
Developing novel processing techniques
Active Compounds and using them to efficiently process and Global Distribution & Extracting + Isolating
prepare active fungal compounds CGMP Manufacturing Active Compounds
Researching + Testing
Robust R+D pipeline including bio synthesis
Novel Medicines via partnerships with leading universities
across the globe
Telehealth Solutions Researching + Testing
International Clinical Trials led by the Data & Analytics Novel Medicines
Clinical Trials
world’s foremost experts and scientific
institutions.
Telehealth Solutions Virtual therapeutic programs, advanced tracking,
Data & Analytics digital mental healthcare via Mindleap Health Clinical Trials
Distributing across North America
Global Distribution &
CGMP Manufacturing and other regions of the globe
with our established partners and affiliates Medicine Evolved
7Research and Development /
Intellectual Property Portfolio
Understanding the potential benefits of fungi on humans is only just beginning. Medicinal mushrooms
are referenced in some of the world’s first medical texts in China from 200 AD and over the centuries
Eastern Medicine has utilized many of these species as fundamental wellness remedies. But now,
modern science is finally discovering and identifying these active compounds for their medicinal and
pyschedelic therapeutic properties and what they can do to better the human vitality. Mydecine is
well positioned to continue to lead this charge.
Two broadly defined, complementary approaches to:
Compound First, Indication Second Pairing Associated Technologies to leverage
synergy of utility, use and production
v
✓Psychedelics ✓Functional & Medicinal
Ability to cultivate, extract, conduct R&D, import and 30K square foot extraction,
export full cGMP certified pharmaceutical grade natural chromatography, and analytics lab
and synthetic psilocybin and other tryptamines
7.5K square foot mycology- chemistry,
Seven pending patents covering thousands of inventions genomics, tissue culture R&D laboratory
Dosage forms and formulations for better control
Pharmaceutical Grade extract purification matched
of time course, potency and effect
with solubilization IP for enhanced bio-availability
Understand and map the Entourage Effect
Formulations designed to scale
Novel production methods: synthetic or nature-sourced
Large scale distribution network Medicine Evolved
Methods of synthesis, solubility
8Partnerships & Facilities
Our partnership with API, enables Mydecine to field unparalleled studies with precise
control and ownership over study design and drug format. We utilize the data both
for our own work and to further collaboration with academic leaders in the field.
World Class Research Facility
✓Health Canada Scheduled 1 Drugs and Substances Dealer’s License
✓ 30 + Ph.D.’s, scientists, clinicians, regulatory, patent experts
✓Drug Design, target discover, validation
✓Analytical testing, performance characterization
✓Medicinal chemistry and synthesis
✓School of Pharmacy recognized expertise
✓Ensures clinical study drug supply, all schedule classes
✓Cultivation of psilocybin producing mushrooms
✓Access to hospital network for enablement of clinical research
✓Hundreds of millions of dollars in lab infrastructure
✓Ability to cultivate, extract, conduct R&D, import and export full cGMP certified Medicine Evolved
pharmaceutical grade natural and synthetic psilocybin and other tryptamines
9Mydecine Center of Mycology
Laboratory & US Headquarters
Denver, Colorado, USA
✓ 30,000 sq. ft pharmaceutical grade extraction lab
✓ 7500 sq. ft state-of-the-art mycology lab
✓ Full cultivation and extraction capabilities
✓ Genetic research, IP, product development
✓ Production of all fungi medicinal compounds
✓ Analytical chemistry, genomics, tissue culture
✓ GMP-compliant SOP production processes
✓ Planned expansion to research psilocybin under DEA Licensure
Medicine Evolved
10Partnerships & Resources
Medicine Evolved
11Technology
Mindleap Health's platform combines the power of any time and
anywhere virtual treatments via a smartphone with the power of
mental health analytics and soon artificial intelligence to disrupt
and improve current treatments.
The company plans to grow in the next 12 months by:
✓ Offering 10 Mental Health and Wellbeing programs as in-app purchases
✓ Expanding specialist network from 60 to 1000
✓ Expanding partner network from 3 to 100
✓ Expanding Organic Social Media Impressions from 45,000 to 250,000 a month
✓ Combining wearable data to provide more precise and data-driven care to users
✓ Launching AI capabilities to predict mental health states and provide behavioural
based mental health interventions
✓ Currently thousands of active application users Medicine Evolved
12Intelligent technology systems built to sense mental
health states to maximize the treatment outcomes
Collect application usage metrics along
with social phone utilization metrics like
calls and texts.
Collect routine data like sleep,
movement and exercise Phone
Utilization Analyze data with
machine learning.
Activity Patterns AI Analysis
Predict user state and
Connect to wearables to track daily
behavior to optimize support
activity and biometric information.
and predict best treatment
response.
Wearables Define State
• Digital Phenotyping • Clinically viable solutions first
Mindleap will be monitoring how a user interacts with their Mindleap will begin collecting its initial dataset through the launch
smartphone using an artificial intelligence machine learning of the platform and will launch passive data tracking features once
data model to make accurate predictions about mental health platform launches.
state.
• User privacy and security
• Research backed methodologies Mindleap is committed to preserving the privacy and confidentiality
Over the past two decades, research on digital phenotyping of users and will not sell or license any data.
for mental health has been increasing, offering substantial
insight into optimal methodologies, research goals, and Medicine Evolved
patient outcomes. 13Market Comparison M E D I C I N E E V O L V E D
Possess a Schedule 1 Substances and Drugs
Dealer’s License to legally research psilocybin NO NO NO NO
Able to import / export whole mushrooms
containing psilocybin NO NO NO
Have direct cGMP lab access for R&D NO NO NO
Have direct access to a virtual telehealth
app for psychedelic after-care NO NO NO NO
remote therapy
Collaborating with Military personnel NO NO NO NO
Developing and producing non-psychedelic
fungtional™ mushroom products for NO NO NO
the retail market
Have a dedicated state-of-the-art NO NO NO NO
mycology lab
Developing IP for patent filings
Researching psilocybin for PTSD,
Addiction, Depression, Anxiety, NO NO NO NO
and headaches
Studying mushroom genome sequencing NO NO NO NO
Using high-grade nanotechnology compound
delivery mechanisms for increased NO
bioavailability
Clinical Trials - Clinical Trials - Clinical Trials - Clinical Trials - Clinical Trials -
Stage of clinical trials
Phase 2A Phase 2B Phase 2B Phase 2A Phase 2B
1
*MARKET CAP
* As of 12-22-20
$65.21M (CAD) $286.2M (CAD) Private $1.3B (CAD) $2.4B (CAD) 14Q2 Q3 Q4
2020 2020 2020
M E D I C I N E E V O L V E D
Company Milestones Evolution Clinical Trials Patent Filings
World’s first cGMP pharmaceutical
Established a R&D partnership with grade fungal derived psilocybin sold and
Applied Pharmaceutical Innovation exported to leading research institution
through the faculty of drug discovery and pharmaceutical
medicine out of the University of Alberta 3rd Clinical Trial
Universiy of Alberta
Non brokered Psilocybin assisted Psychotherapy
1st Clinical Trial close for $2.6M in PTSD / Veterans ( Dr. Yambo Zhang ) First Commercial
Acquired Mindleap Health 5 Patent Filings ethica CRO Export of Legal
Leiden University
advanced digital wellness, therapeutic,
and psychedelic integration platform Psilocybin assisted Psychotherapy
Launch Mindleap platform engagement Psilocybin Mushrooms
sessions start happening on platform
including mental health data capture in PTSD / Veterans ( Dr. Eric Vermetten)
Company
Founded Q2 - 2020 Q3 - 2020 Q4 - 2020
Cannacord brokered gross Acquired NeuroPharm 2nd Clinical Trial
2 Patent Filings
proceeds 2.4M adding valuable intellectual property and University of Western Ontario
First rare species of novel psychedelic medicine ready to go into Psilocybin assisted Psychotherapy
psilocybin producing mushrooms
clinical trials to focus on PTSD in veterans in PTSD / Veterans (Dr. Ruth Lanius) ProPharma Group
arrive onsite at U of A Built out a 7,500 sq. ft.
Engagement
state-of-the-art 4th Clinical Trial
mycology laboratory in Royal Ottowa Hospital
Denver, Colorado Psilocybin assisted Psychotherapy
in PTSD / Veterans (Dr. Rebecca Robillard)
Medicine Evolved
15The Mydecine Advantage
✓ A leader in the emerging psychedelic health and fungtional™ vitality
product markets
✓ Sophisticated domestic and international partnerships
✓ Multiple, complementary initiatives leveraging psilocybin based
science and technologies
✓ Management team with track record of multiple successful exits
✓ Robust clinical pipeline across a range of global sites
✓ Uniquely positioned to address large unmet needs,
such as Veteran PTSD
✓ Unparalleled access to Veteran organizations and military
establishments
✓ World-renowned SAB, thought-leaders spanning multiple disciplines
✓ Established record of sourcing non-dilutive funding – DARPA, DoD,
philanthropic
✓ Well-defined 18-month value inflection trajectory and news flow
Medicine Evolved
1620Mydecine Innovations Group Inc. ( MYCO) .39
Financial Highlights
Issued & Outstanding
166,720,845
Reserved for Issuance
24,851,122
Symbol / Trading Market :
( CSE: MYCO ) (OTC : MYCOF ) ( FSE : 0NFA )
Total I/O Warrants : 1,743,000
Total I/O Options : 3,343,157
52 - week - High and Low : 1.15 - 0.04
Average Daily Trading Volume : 552.68K
Market Cap : 65.21M
Status: Active
Industry : Life Sciences Medicine Evolved
17Leadership M E D I C I N E E V O L V E D
Joshua Bartch, Director, CEO & Chairman
Dean Ditto, CFO
Joshua Bartch is Director, CEO & Chairman of Mydecine Innovations Group. Mr.
Dean Ditto is the Chief Financial Officer for Mydecine. He brings a wealth
Bartch's entrepreneurial career took off in 2009 when he co-founded
of experience including SEC reporting, risk management, internal audit
AudioTranscriptionist.com and founded the Denver based dispensary, Doctors
controls and building compliance functions for regulated companies. He
Orders. Following these ventures, Mr. Bartch founded a boutique investment firm
recently led a financial services company business turnaround resulting in
that operated throughout the U.S. and Canadian markets. In 2014, Bartch co-
improved profits of $15 million. As well as, structuring a vertically
founded Cannabase.io, the USA's most significant legal and sophisticated cannabis
integrated business unit resulting in increased profits of $10 million
wholesale platform. Mr. Bartch took successful exits from AudioTranscriptionist.com,
Doctor’s Orders and Cannabase.io.
Dr. Rakesh Jetly, OMM, CD, MD, FRCPC, Chief Medical Officer
Damon Michaels, Director, COO & Co-Founder
Dr. Jetly is currently the Head of the Centre of Excellence on Mental Health in
Damon Michaels is the Chief Operations Officer of Mydecine Innovations Group. Prior to
Ottawa, Ontario, and an associate professor of psychiatry at Dalhousie University
joining MIG, Mr. Michaels was consulting for various hemp businesses through his
(Halifax), and the University of Ottawa. He has published numerous articles in
company, Emerald Baron. Before that, he served as GM for the leading multi-platform
professional journals and presents nationally and internationally on such topics as
cannabinoid research and technology firm based in Colorado called ebbu. In November of
post-traumatic stress disorder and operational psychiatry. Dr. Jetly has previously
2018, ebbu was acquired for CAD$429m by Canopy Growth for being the cutting edge
held various professional positions as a psychiatrist, including: Director of the
leader in cannabinoid science. Over the last decade, Mr. Michaels has been in leading roles
“Operational Trauma and Stress Support Centre,” Atlantic Region (2000-2008);
with multiple large brands throughout the cannabis vertical in Colorado and California.
Chief Resident in Psychiatry, ͘
St Michael’s Hospital (1999-2000); and Senior Medical
Outside of the cannabis industry, he developed a national snowboard brand with his team,
Officer for the “Canadian Contingent United Nations Middle East” in Israel
was one of four entrepreneurs who created Colorado’s first-ever glass recycling company,
(1993-1994).
and was on the business development team for a Google Ventures Company.
Robert Roscow, MA, CSO & Co-Founder
James Gunning, CMO
Robert Roscow is the Chief Scientific Officer of Mydecine Innovations Group. As a highly
Jim Gunning is the CMO of Mydecine Innovations Group. Mr. Gunning has significant
educated geneticist, he has spent his academic and professional careers looking for
experience in senior marketing and leadership roles. He was one of the first hires at Red
valuable and unique medicinal molecules found in nature. The last two companies that
Bull North America. In his 10 years with the brand he had a significant role in their success
Robert applied his innovations to were Canopy Growth and ebbu where he ran their
as a Director of Marketing in their HQ office. He has since worked with several other major
genetics divisions. Mr. Roscow has already leveraged an expertise in genomics, evolution
brands developing significant strategic marketing and partnership initiatives and has
and molecular biology to maximize the industrial production of cannabinoids and their use
worked with multiple start ups.
in a pharmacological context.This work has resulted in multiple patent filings and accolades
in publications ranging from Nature to Rolling Stone. Now, Mr. Roscow has set his focus on
the vast healing potential of fungi.
1
18Medicine Evolved
Leadership
Gordan Neal, Independent Director
Nikolai Vassev, Founder of MindLeap Health
Mr. Neal has extensive experience in the metals and mining sector, capital markets and
government communications. He was most recently the Vice President of Corporate Strong track record with high-growth tech companies, forming multi-million-
Development for Silvercorp Metals Inc., New Pacific’s largest shareholder. Previous to dollar partnerships, leading complex data analytics and cyber security
that role he held the same position at MAG Silver Corp. Mr. Neal’s career also saw him software projects for various Fortune 500 organizations, as well as for the
working in the Office of the Prime Minister of Canada as a senior communications US and Canadian Governments.
advisor. Mr Neal is responsible for investor relations, the coordination of capital markets,
and government communications.
Michael Connolly, J.D., CCO, General Counsel William Cook, System Architect & Project Manager of Mindleap Health
Michael Connolly is the Chief Compliance Officer and General Counsel for Mydecine BS, USMA at West Point; MA Trinity College. Award-winning Engineering
Innovations Group. He has a 28-year extensive background in corporate law, finance, and Leader. Led teams that sold and developed four multi-billion dollar projects -
transactional law, as well as commercial litigation. Mr. Connolly has served as counsel and all with built-in AI. System Architect for successful exit: Starbelly.com $240M.
advisor for numerous start-up companies, including companies in the cannabis and CBD Lead Engineer of THAAD BM/C3I, Litton (230+ engineer team); Mgr. Patriot
industries. He has been responsible for managing complex financial transactions, Missile System C2, Raytheon; Founder & President, Intelligent Systems
compliance and regulatory matters, and investor relations. Juris Doctorate from Creighton Research, Inc.; Founder & CEO, Tempi.com
University School of Law and is licensed to practice law in Colorado, Florida, and Nebraska.
Jack Bunch, Head of Digital of Mindleap Health
Cynthia Salarizadeh, PR
Cynthia Salarizadeh is the head of public relations for Mydecine Innovations Group. Jack helped launch Triage.com, the world's first and largest predictive AI
She has more than 20 years experience in strategic communications and mass media Dermatology Platform, along with several other startups in the high-tech
relations. Cynthia is the founder of the newswire and entrepreneur tech suite, AxisWire, and healthcare space. Jack has also helped develop and lead marketing
as well as the luxury brand House of Saka. She is also the Co-founder of cannabis finance projects for multinational banks and technology companies.
news publication Green Market Report. KCSA Strategic Communications acquired her
leading cannabis and hemp public relations firm Salar Media Group.
Kevin Darabi, Creative Manager Michael Cook, Software Design Manager of Mindleap Health
BA, CSUF; Creative Advertising. Kevin has proven success driving award winning creative BA, SDSU; MA in Media Design, Full Sail Univ; Award-winning Designer. Serial
marketing campaigns through direct and indirect digital content marketing. Mr. Darabi has Entrepreneur, Creative Project Manager and Expert Strategist in Sales, Branding &
branded several well-known lifestyle and consumer product brands. He began his career Marketing, Advertising, and UX/UI Design. Team Builder, Mentor and Design Lead.
as a graphic artist and developed a wide variety of skills working for companies such as Founder of CreativeTalent.com; Chief Design Officer and Founder of Tempi.com.
Tilly’s Corp., Hot Wheels, Quiznos, Quiksiilver and T-mobile.
191Medicine Evolved
Medicine Research & Development Team
Dr. Brian Duff Sloley, BSc, MS, PhD
Dr. Sloley holds a PhD in Biology from the University of Waterloo and has over 35
Dr. Raimar Löbenberg, BSc (Pharm), PhD
years of experience in analytical research and product development including Dr. Raimar Löbenberg is an expert in area of pharmaceutics, drug development and delivery. He is a
positions at the University of Saskatchewan’s Neuropsychiatric Research Unit, member of the United States Pharmacopoeia (USP) expert committee for Dietary Supplements and
Novokin Biotech, Sinoveda, and Radient Technologies. Dr. Sloley’s specialities Herbal Medicines and chair of the subcommittee for performance testing of dietary supplements,
include comparative neurobiology with a focus on neurotransmitter identification, member of the American Association of Pharmaceutical Scientists (AAPS) Steering Committee for
metabolism and disruption as well as botanical composition. Dr. Sloley has Drug Release and Dissolution Testing and vice chair of Speciality Committee for Pharmaceutical
extensive experience working in analytical biochemistry in a GLP setting including Quality of Traditional Medicines of the World Foundation of Traditional Chinese Medicines, and a
HPLC, LCMS/MS, UV absorbance and fluorescent detection. In his spare time Dr. past president of the Canadian Society for Pharmaceutical Sciences. Dr. Löbenberg is serving as
Sloley is an active member of the Alberta Mycological Society and will be Mydecine’s expert in controlled substances, formulation, and GMP manufacturing.
instrumental in characterizing and discovering new potent compounds as well as
working with Society to source novel fungi.
Dr. Vijay Somayaji, BSci, PhD
Dr. Kevin Morin, BSc(Pharm), MD, PhD, FRCP(C) Dr. Vijay Somayaji has over 30 years of combined academic and biotech industry experience in various
Dr. Morin is a psychiatrist and is currently site lead for the rTMS neuromodulation service areas, including research and development, product development, and quality assurance and quality
at Alberta Hospital Edmonton (AHE). He also has an inpatient practice at AHE and has control. She obtained her Ph.D. in Chemistry from Indian Institute of Science and did her post-doctoral
an outpatient practice at Precision NeuroClinics performing neuronavigated rTMS and work with Dr. H.C. Brown (Nobel Laureate) at Purdue University (USA). At University of Alberta she
research in Ketamine. He is Assistant Clinical Professor in the Department of Psychiatry worked as a research associate with Dr. L.I. Wiebe (Faculty of Pharmacy and Pharmaceutical Sciences)
at the University of Alberta and is Adjunct Professor in the Faculty of Pharmacy and before joining Biomira Inc. as a senior scientist. She has since worked as a manager of Product
Pharmaceutical Sciences where he has a pharmaco-EEG imaging and VR/AR laboratory Development at AltaRex Corp., as a Director of Product Development at Novolytic Inc., as Director of
at API. Dr. Morin’s pharmaco-EEG imaging expertise will be instrumental in enabling Drug Development at Virexx Medical Corp., and as a Quality Assurance and Quality Control consultant
Mydecine to determine potential activity of various extracted compounds on the brain in for IMbiotechnologies Ltd. Dr. Somayaji is serving as QA/QC for Mydecine’s clinical manufacturing.
vitro.
Dr. Rakesh Bhat, BSc, MSc, PhD Antonio Bruni, BSci, PhD, PM Cert.
Dr. Bhat graduated magna cum laude from Leipzig University with a PhD in bio-analytical Dr. Antonio Bruni over a decade of experience managing commercial research and development in
chemistry, molecular biology, and biochemistry. Dr. Bhat has spent two decades working industry and academia. He completed his BSci Cum Laude at Lake Superior State University and a
in translational research, including the development of niche bioanalytical capacity such PhD in experimental surgery under world renowned clinician-scientist, Dr. James Shapiro, developer
as a novel adult human ventricular cardiomyocyte cell line(s) stably expressing hERD and of the “Edmonton Protocol” at the University of Alberta, in addition to serving as quality coordinator
Nav1.5 using electrophysiology and other cell lines for a wide range of industry projects. for Dr. Shapiro’s trials. While working in industry for Sernova Corp, Dr. Bruni co-authored Health
In his previous role Dr. Bhat worked under nobel lauriate Michael Houghton. Dr. Bhat has Canada submissions for phase 1 and 2 clinical trials and managed Sernova’s product pipeline
extensive translational project management experience and as API’s director of laboratory analysis. Dr. Bruni is serving as project manager for the team working on Mydecine’s DMF and IB.
services will be key the key member of the team facilitating and implementing Mydecine’s
pre-clinical product development. 20
1M E D I C I N E E V O L V E D
Legal Contacts
Ellenoff Grossman & Schole LLP (USA):
Address: 1345 6th Ave, New York, NY 10105, United States
Email: https://www.egsllp.com/contact
Tel: +1 212-370-1300
Miller Thomson (Canada):
Address: Scotia Plaza, 40 King Street West, Suite 5800, Toronto, ON, M5H 3S1, Canada
Email: toronto@millerthomson.com
Tel:416.595.8500
Toll Free: +1 888-762-5559
Fladgate (EU):
Address: 16 Great Queen St, Holborn, London WC2B 5DG, United Kingdom
Email: fladgate@fladgate.com
Tel: +44 20-3036-7000
Auditor:
MNP:
Address: Suite 2000, 330 5th Ave. S.W., Calgary, AB, T2P 0L4
Email: proposalteam@mnp.ca
Tel: +1 403-444-0150
Medicine Evolved
21Charles Lee / Investor Relations
corp@mydecineinc.com
www.mydecine.com
THANK YOU.
M E D I C I N E E V O L V E D
Founded March 2020
USA Office Canada Office
1250 S. Parker Rd. 789 W Pender St.
Lower Level, Suite A Suite 810
Denver, CO 80231 Vancouver, BC V6C 1H2
@mydecineinc @mydecineig @mydecineig @mydecineM E D I C I N E E V O L V E D
Medical, Scientific and Technology Advisory Board
Denton Hoyer, Ph.D. Eric Vermetten, Prof. Dr. H.G.J.M. MD,
Rick Barnett Psy.D., MA, MS, LADC
Dr. Hoyer has been involved in drug discovery at leading
Ph.D. Colonel
Clinical psychologist who is an expert in addictive disorders
pharmaceutical companies and research institutions for the last 30 Dr. Vermetten is professor of Medical-Biological
(including sex, drugs and food addiction) and problems such as
years. He holds numerous patents and has been published and Psychiatric Aspects of Psychotrauma, LUMC/
depression, anxiety, and relationship difficulties. Rick has
extensively in the field of medicinal chemistry and drug research. Dr. University of Leiden. The chair was established
experience in a range of approaches to treating problems
Hoyer has unparalleled expertise in computational chemistry by Arq Psychotrauma Research and the Dutch
related to addictive behaviors.
enabled probe molecule design, drug design and optimization, Ministry of Defense. Eric Vermetten is an active
synthetic planning and execution, evaluation of chemical novelty clinical psychiatrist at the MGGZ in Utrecht
and intellectual property (Military Mental Health care).
Danielle Wise, Ph.D. Zul Meraly, Ph.D.
30 years of psychotherapy, mental health coaching, Robin Carhart-Harris, Ph.D. Dr. Zul Merali was President/CEO and Scientific Director
and therapy work with thousands of clients. Significant of the University of Ottawa Institute of Mental Health
experience in psychedelic aftercare and utilizing Leads Imperial College London’s Centre For Psychedelic
Research. He was also full professor in the faculties of
telemedicine tools in her practice. Research. Regularly publishes research on psychedelic
Medicine (Departments of Cellular and Molecular
medicines in clinical perspectives
Medicine and Psychiatry) and Social Sciences
(Psychology) at the University of Ottawa, as well as
research professor at the Institute of Neuroscience at
Carleton University.
Gary H. Wynn, MD, COL, MC, USA Sandy McFarlane, MBBS (Hons), MD, Dip. Psychother,
FRANZCP Malireddy Srinivasulu Reddy, Ph.D.
Dr. Gary Wynn is Professor of Psychiatry and Neuroscience,
The Director of The University of Adelaide's Centre for Traumatic As a 7-time Nobel Peace Prize Nominee, Dr. Reddy
Assistant Chair of the Department of Psychiatry, and Senior
Stress Studies, Professor McFarlane's area of particular specialty is the founder and president of Denver-based
Scientist at the Center for the Study of Traumatic Stress. He is
has been the effects of traumatic stress and is an international American Dairy and Food Consulting Laboratories
also a Distinguished Fellow of the American Psychiatric
expert in the field of the impact of disasters and posttraumatic and International Media and Cultures (IMAC Inc.).
Association and on the editorial board of the Journal of
stress disorder (PTSD). His research has focused on the He holds over 150 U.S. and international patents
Neuroscience Research. Dr. Wynn received his education at
epidemiology and longitudinal course of PTSD as well as the and has published over 80 scientific articles on
the United States Military Academy at West Point and
neuroimaging of the cognitive deficits in this disorder. He has dairy starter cultures, probiotics, pharmaceuticals,
Uniformed Services University of the Health Science.
published over 250 articles and chapters in various refereed and complementary alternative medicines
journals and has co-edited three books
pertaining to probiotics.Medical, Scientific and Technology Advisory Board
Ruth Lanius, MD, Ph.D David Erritzoe, MD, Ph.D., MRCPsych
Professor of Psychiatry is the director of the post-traumatic NIHR Academic Clinical Lecturer in General Psychiatry in
stress disorder (PTSD) research unit at Western University. Neuropsychopharmacology and Psychedelic Research
Established the Traumatic Stress Service and the Traumatic Centres, Division of Psychiatry, Dpt of Brain Sciences,
Stress Service Workplace Program, services that specialize in Imperial College London.
the treatment and research of PTSD.
Carl Castro, Ph.D
Carl Castro is the research director for the
Paul Frewen, MD Ph.D. USC Center for Innovation and Research
Anton Gomez-Escolar, MA, MSc
Dr. Frewen joined the departments of psychiatry and on Veterans and Military Families. Castro
Psychopharmacologist, a Member of the UNAD commission has served in a variety of research and
psychology at the University of Western Ontario in
on international drug policy. Advisor to large pharma and leadership positions, including commander
London, Ontario, Canada in September 2008. He
completed his doctorate in clinical psychology at nutraceutical companies, investment firms, and government of the U.S. Army Medical Research Unit-
Western and his post-doctoral residency at the Royal committees on public health. Europe in Heidelberg, Germany; chief of
Ottawa Mental Health Centre. the Department of Military Psychiatry at the
Walter Reed Army Institute of Research in
Washington, D.C.; and director of the
Yanbo Zhang Ph.D Military Operational Medicine Research
Vince Polito, Ph.D. Program, Headquarters, U.S. Army Medical
Dr. Zhang is a clinician-scientist and psychiatrist at the University of
Cognitive Science Researcher at Macquarie University, Research and Materiel Command, Fort
Alberta, with a focus on molecular biology, neuropharmacology, and
Detrick, Md.
Australia with significant experience in psilocybin microdosing neuroscience. Dr. Zhang’s research is primarily focused on the
research. In 2019 led & conducted one of the largest to date impacts that novel interventions such as psychiatric medications and Castro has authored more than 150
systematic study of microdosing psychedelics. brain stimulation treatments have on brain development and brain scientific articles and reports in numerous
recovery or repair. research areas and currently serves as
chair of a NATO research group on military
mental health training. He serves as an
advisor for several Department of Defense
Mohyuddin Mirza Ph.D, P.Ag John Bradley, Ph.D research panels focused on psychological
Dr. Mirza is a botanist who brings over four decades of Dr. Bradley is a retired US Army Psychiatrist and combat veteran with 26 health.
experience and industry knowledge to greenhouse years on Active Duty before joining the VA Boston Healthcare System in
technologies. Dr. Mirza holds a Ph.D. from the University of 2011. He is board-certified in Psychiatry and has focused his career on
Alberta and served as an adjunct professor at his alma matter. suicide prevention and combat trauma.
Medicine Evolved
1You can also read
